Institute of Molecular Medicine, College of Future Technology, Peking University, Beijing, China.
Research and Development Department, Beijing Dingchengtaiyuan (DCTY) Biotech Co., Ltd., Beijing, China.
Front Immunol. 2023 Mar 31;14:1140623. doi: 10.3389/fimmu.2023.1140623. eCollection 2023.
Owing to their antitumor and major histocompatibility complex (MHC)-independent capacities, γδ T cells have gained popularity in adoptive T-cell immunotherapy in recent years. However, many unknowns still exist regarding γδ T cells, and few clinical data have been collected. Therefore, this review aims to describe all the main features of the applications of γδ T cells and provide a systematic view of current γδ T-cell immunotherapy. Specifically, this review will focus on how γδ T cells performed in treating cancers in clinics, on the γδ T-cell clinical trials that have been conducted to date, and the role of γδ T cells in the pharmaceutical industry.
由于 γδ T 细胞具有抗肿瘤和主要组织相容性复合体(MHC)非依赖性的特性,近年来在过继性 T 细胞免疫治疗中受到关注。然而,γδ T 细胞仍存在许多未知因素,且收集到的临床数据较少。因此,本综述旨在描述 γδ T 细胞应用的所有主要特征,并对当前的 γδ T 细胞免疫治疗进行系统综述。具体而言,本综述将重点介绍 γδ T 细胞在临床治疗癌症方面的表现、迄今为止开展的 γδ T 细胞临床试验,以及 γδ T 细胞在制药行业中的作用。